| Literature DB >> 24624139 |
Miguel Roehrs1, Cassieli Gehlen Figueiredo2, Mariane Magalhães Zanchi2, Guilherme Vargas Bochi3, Rafael Noal Moresco4, Andréia Quatrin1, Sabrina Somacal1, Lisiane Conte2, Tatiana Emanuelli1.
Abstract
The present study investigated the effects of oral administration of annatto carotenoids (bixin (BIX) and norbixin (NBIX)) on glucose levels, lipid profiles, and oxidative stress parameters in streptozotocin (STZ)-induced diabetic rats. Animals were treated for 30 days in the following groups: nondiabetic control, diabetic vehicle, diabetic 10 mg/kg BIX, diabetic 100 mg/kg BIX, diabetic 10 mg/kg NBIX, diabetic 100 mg/kg NBIX, diabetic metformin, and diabetic insulin. Blood glucose, LDL cholesterol, and triglyceride levels were reduced in the diabetic rats treated with BIX. BIX treatment prevented protein oxidation and nitric oxide production and restored superoxide dismutase activity. NBIX treatment did not change most parameters assessed, and at the highest dose, it increased LDL cholesterol and triglycerides levels and showed prooxidant action (increased protein oxidation and nitric oxide levels). These findings suggested that BIX could have an antihyperglycemic effect, improve lipid profiles, and protect against damage induced by oxidative stress in the diabetic state. Because NBIX is a water-soluble analog of BIX, we propose that lipophilicity is crucial for the protective effect of annatto carotenoids against streptozotocin-induced diabetes.Entities:
Year: 2014 PMID: 24624139 PMCID: PMC3929283 DOI: 10.1155/2014/839095
Source DB: PubMed Journal: Int J Endocrinol ISSN: 1687-8337 Impact factor: 3.257
Figure 1Chemical structure of annatto seed carotenoids.
Figure 2Blood glucose (a) and fructosamine levels (b) and body weight (c) of streptozotocin-induced diabetic rats. Blood glucose levels and body weight were assessed at the onset and end of treatment with vehicle, bixin, norbixin, insulin, or metformin. Fructosamine levels were assessed at the end of the treatment. Data are expressed as means ± SEM (n = 6 per group). ANOVA followed by Duncan's test: *P < 0.05 versus the respective nondiabetic control; # P < 0.05 versus the respective diabetic vehicle. BIX 10: 10 mg/kg bixin; BIX 100: 100 mg/kg bixin; NBIX 10: 10 mg/kg norbixin; NBIX 100: 100 mg/kg norbixin.
Figure 3Lipid profile of streptozotocin-induced diabetic rats: total cholesterol (a), HDL cholesterol (b), LDL cholesterol (c), and triglycerides (d). Data are expressed as means ± SEM (n = 6 per group). ANOVA followed by Duncan's test: *P < 0.05 versus nondiabetic control; # P < 0.05 versus diabetic vehicle. BIX 10: 10 mg/kg bixin; BIX 100: 100 mg/kg bixin; NBIX 10: 10 mg/kg norbixin; NBIX 100: 100 mg/kg norbixin.
Figure 4Oxidative stress parameters of streptozotocin-induced diabetic rats: AOPP levels (a), nitric oxide levels (b), superoxide dismutase (SOD) (c), and catalase activity (CAT) activity (d). Data are expressed as mean ± SEM (n = 6 per group). ANOVA followed by Duncan's test: *P < 0.05 versus nondiabetic control; # P < 0.05 versus diabetic vehicle. BIX 10: 10 mg/kg bixin; BIX 100: 100 mg/kg bixin; NBIX 10: 10 mg/kg norbixin; NBIX 100: 100 mg/kg norbixin.
Effect of bixin and norbixin treatment on oxidative stress parameters in the blood of streptozotocin-induced diabetic rats.
| Groups | GPx | GR | TrxR |
|---|---|---|---|
| Nondiabetic control | 26.3 ± 5.9 | 20.6 ± 1.2 | 155.5 ± 8.2 |
| Diabetic vehicle | 25.0 ± 1.6 | 32.0 ± 0.7 | 138.0 ± 16.5 |
| Diabetic + insulin | 49.6 ± 9.2∗,# | 18.2 ± 2.9 | 172.7 ± 21.3 |
| Diabetic + metformin | 29.8 ± 8.3 | 23.9 ± 11.1 | 142.1 ± 11.4 |
| Diabetic + bixin (10 mg/kg) | 11.4 ± 3.7 | 19.2 ± 3.9 | 149.8 ± 6.5 |
| Diabetic + bixin (100 mg/kg) | 19.7 ± 6.5 | 61.8 ± 10.9∗,# | 264.3 ± 27.0∗,# |
| Diabetic + norbixin (10 mg/kg) | 26.0 ± 9.5 | 18.0 ± 1.2 | 96.3 ± 11.2∗,# |
| Diabetic + norbixin (100 mg/kg) | 62.2 ± 3.2∗,# | 17.2 ± 2.3 | 150.9 ± 12.7 |
Data are expressed as means ± SEM (n = 6 per group, except for the metformin and insulin groups that had 5 animals). ANOVA followed by Duncan's test: *P < 0.05 versus nondiabetic control; # P < 0.05 versus diabetic vehicle.